Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The New Da Novo submission is....Coming
This PoNS Neurostimulation Device is going to pass the FDA submission.
So what are they trying to say, the patients were reaching some of these goals without the use of the PoNS neurostimulation device. The difference is that all of these patients didn't start the PoNS neurostimulation not until after 12 months after their brain injuries, then they started the program. IMO, I guess the FDA wanted half in the study to be treated with the PoNS neurostimulator device and the other half to be treated with Physical Therapy sections not using the PoNS Device. Make sense. Next complete a trial study of Patients whom have completed Physical Therapy and enroll them into the PoNS neurostimulator device Clinical study and see how well they benefited from using the PoNS device after going thru PT. What percentage of patients benefited from the PoNS Device, and what percentage of patients did not benefit from the device.
Then on the other hand I can see while Helius Medical Technologies Inc sent in their NDA for PoNS Device because they use Patients 12 months after their injuries and not before. IMO the reason why the FDA did not have enough evidence to support Helius study of the PoNS. Maybe if they would've started the study from start of traumatic injuries mild to moderate injuries, in both physical therapeutic to using the PoNS Device and a study of Patient using PT without PoNS device. Helius Medical Technologies inc would probably have an FDA Approval for the PoNS neurostimulation Device.
Please, Correct me if I'am wrong.
That is a huge bid that show up at .965 share price should start soaring back over $1 and back to $2 on Next Physical therapy new release from Mild to moderate patients whom suffered from traumatic brain injure. Last week release news from study shown 73% of patients who had traumatic brain injuries show a difference in balance when walking and gait after use of PoNS Device the Neurostimulation. This was just one study report taking from Winconsin Madison University. Helius Medical Technologies Inc will be releasing more studies of Patients receiving the PoNS Treatment to stimulate their nerves from mild to moderate brain injuries to support the the Physical and therapy each patients received from the neurostimulation device. Evidence the FDA board is looking for as address in the CRL the physical and therapy.
Yes, the news has to be huge for ONCY to a 59% run today and never look back. Still holding after buying back 1.97 today.
Holding News is due. Company stated that will be releasing information on clinical data in 4th quarter of 2019. I'm waiting.
Looking to ad a couple thousand share each week now that Evoke has re-submit NDA for Gimoti. Look for a class 1 FDA 2 months time approval.
NDA RE-Submission of Gimoti, follow by FDA Approval follow by Huge Profits.
Guys don't forget to load up stock EVOK. My dad says 1 to 15 days left before Evoke Pharma Inc re-submission NDA for Gimoti. Gimoti is a safe Nasal spray form of metroclopramide a drug use to treat symptoms of Gastroparesis. Most patients suffering from Gastroparesis usually are patients with diabetes and 85% of the patients with Gastroparesis are women. When FDA approve Gimoti it will be the most advance treatment for Gastroparesis suffers in over 40 years.The re-submission will take place anytime from December 17 through December 31st, within 15 days from now. Good Luck.
For you moms everywhere who are fighting breast cancer. NantKwest is testing a new treatment that can prolong life longer for those who are suffering triple negative cancer. Hope is on its way. And don't you shorts dare short NantKwest who has created a breast cancer treatment that will and can give a mother suffering with breast cancer more time to be with her children and families. Have a conscious over money on this one.
I'm glad I made my money and bail. I never know Chamber Energy to do a good job. Glad they were kind to shareholders and buyers today.
CEI might see $3 again today.
Shorts working together in after hours. Sitting on the Ask at 1.12 making everyone go around them and hit the bid if they really want out. So many shareholders are falling for it. I prefer to wait after the Big event December 7th to 10th. I wish I had extra funds to take out that 1.12 Ask.
Some one liked the news the share price made a very fast jump from 1.11 to 1.22 in a matter of seconds. I had my sell order much higher. Look for a PR regarding the commercial low nicotine tobacco application approval by the FDA soon. Then shareholders will see a large increase in share price. it is the FDA commercial approval for 22nd Century Group Inc low Nicotine tobacco many investors are waiting on. Then we will see large buyers and investors coming into 22nd Century Group. I read the news could come at anytime, because the Conference Call stated the FDA is moving the process of approval for the commercialization for low nicotine tobacco thru the review process.
The waiting for FDA approval is making me want to grab a cigarette. LOL
NEWS OUT.
this stock use to be over $5 less than 7 months ago. Now look where it is now. Down in the bottomish pits. Thanks InspireMD, iNC.
I rack up on Sorrento Therapeutics, Inc yesterday, made huge Bank.
Huge volume from the jump off, until InspireMD, inc start dumping as soon as the Bell ring at 9:30 am. The company dumped about 2 million shares in the first hour. That is what kill what could have been a huge payday on a soaring share price for all long terms and the company, plus daytraders. InspireMD inc is to blame for killing the momentum in this run today.
Please get back to $5.
These Tel a viv put out a pr so they can dump. InspireMD inc is one of the most crooked stocks on the USA stock market. The company is a scam to sell shares for their own personal use, and the rest goes to their friends and family member at the company. Which they call over head expense and operating expenses. Guys These are horrible stocks that InspireMD make sound so good. If they're then why they're not generating fair revenue or the medical field is not backing them as much. Because they themselves don't care much for their products. They prefer others products over What InspireMD, inc is selling or providing in the medical field.
This is an ATM company.
Why are we not trading at least $5 a share with the highest offer of $5 a share. Should shareholders vote on this offer. I think we should be able to vote is we accept this offer or not. Offer is still on the table.
The press release stated 2 companies has offer to buyout the shareholders with up to a $5 offer on the table,but the company believe this is a low ball offer. The company states SRNE shares is worth more than the offering price per share.
Resubmission announcement of NDA for Gimoti Nasal Spray will get the share price up there. The News announcement could be release at any time this4th quarter. The company stated in the last 2 Press release they will be resubmission NDA for Gimoti nasal spray this quarter. When they do the Longs and the other shareholders whom bought before this big event is going to be well compensated.
Is this a big FAT scam or what?
Looking for $5 today on great news release.
this baby need to run in order to draw in the buyers. Looking at $5 if market makers and the the company let it run. Could draw in hedge funds.
We received great news today, when the company released a PR that the Qualification department of the NASDAQ Stock market has granted Evoke Pharma Inc a 180 days extension to comply with the NASDAQ RULING to keep the share price above $1. Evoke has until May 11, 2020 to meet compliance. That will be plenty enough time for Evoke Pharma to resubmit NDA for Gimoti and wait for FDA to approve Evoke Pharma Inc Nasal spray form of Metoclopramide that will be known as Gimoti Nasal spray for the treatment of acute and recurrent of Diabetic Gastroparesis disease. A disease which is found in 80% of women with Diabetic Gastroparesis disease.
When approve Gimoti will be the first non oral advancement treatment to treat acute and recurrents Gastroparesis disease in 40 years.
Evoke Pharma Inc Granted 180 NASDAQ Extension until May 11, 2020. Evoke Pharma provided a written response to the Qualification Department of the NASDAQ stock market outlining planned NDA Resubmission this quarter.
I'm loaded and will be holding for approval of Gimoti Nasal spray form of metoclopramide.
We're pulling for her. A family member of mines has the Gastroparesis disease also and the tablet form of metoclopramide is not doing her much good. She is really suffering with this disease. Her upper abdominal stay bloated. It sometimes takes day for her food to be released into her intestines from her stomach. the tablet offer little help. So lets pretension the FDA is they don't pass Gimoti this time around, because the the pain and suffering out weigh the means. Gimoti has been proven to be safe and is a much better form of delivering metoclopramide thorough a nasal spray to treat female patients gastroparesis suffers than tablet form.
Right.
I've been loading Every since March and May and continue to add each week or month including today. I hope you're ready for the resubmission for NDA for Gimoti Nasal spray formular of Metoclopramide. Watch out Reglan tablet form of Metoclopramide is sometimes ineffective for treating Gastroparesis disease. Gimoti Nasal spray form proven in clinical studies is the best way of treating diabetic gastroparesis disease which effect millions which 80% in females with gastroparesis disease usually associated with diabetic gastrointestines.
Let's get that FDA approval this time around Evoke.
In conference call today Iian expect Precipio to generate over $100 millions in revenue next year. He also stated no Offering.On conference call he expect many more customers to order IV cell for their medical institutions, and Universities medical centers to sign up like Harvard and Yale After this year lets say good-bye to $2.55 million quarterly revenue and hello to $25 million quarterly revenue = $100 million annual revenue
Let's hope everything Iian stated in the conference call today come to past for all of us shareholders and investors. No tricks Iian.
NEWS OUT !!
I don't know about that, Illumina is looking at BioNano's Saphyr system. They probably making an offer to buy BioNano out for a lot less than Pacific Biosciences whom price is 1.2 billion dollars. We shall see.
News Out. Another step closer to getting FDA approval. Evoke Pharma has completed the batches of commercial Gimoti in nasal spray method of administrating Gimoti. They're now working on the root cause "The Chemistry". The company is on track of re-submission NDA for Gimoti in the 4th quarter which starts next month.
Glad I keep this one in my account since .30 last month. Should see more continuation. imo.
These little penny stock medical device company like Sonny's laugh at shareholders with their assist surgents and nurses. When they're in the operating room giving someone a false hip or spine. Damn I stuck gold with this little scam company I run. I sale millions of dollars in shares and only make a couple of hundred thousands in revenue on a great month, and these dumb as shareholders believe I have something worth millions that will make them rich. What a couple of nuts. And guess what. I keep reverse splitting their shares and they keep coming back for more. Talking about your gullible. morons.
Short this Bitchen and walk away. That is what I'am doing.
Some one has finally mention it. SiNtx Technologies inc has fail the common individual shareholders.
Yeah, right, a dental partnership, hehee hehee that sounds like a David Chappal Joke. Who is going to put Nitrade Silicon in their month and come out looking like Jaws the vellum on OO7 starting Roger Moore. Sonny and company is just feeding you guys bullchit to keep you tuning in. Wow ! I have not laugh this hard in a long time. hehee hehee hehee!
Sonny and company need to stop with the Jokes. Got you guys believing in the tooth fairy. Those Guys are really really really funny.
No, because We know our Pal Sonny Boy is not going to let it go up pass 1.80.
Short Sellers Rules SiNtx Technologies (SINT) alone with our Pal Sonny.